OR-ASKNICELY
AskNicely , the customer experience platform for people-powered businesses, today announced the opening of its first European office in Amsterdam. The company is headquartered in Portland, Oregon and recently expanded its original office in Auckland, New Zealand.
“Amsterdam has become a hub for innovation,” said AskNicely co-founder and CEO Aaron Ward. “We recognize the potential of the city’s incredible talent pool, its world-class infrastructure, and the vibrant growth that has fueled the Amsterdam tech scene.”
The European office was added in response to customer demand, and to accelerate the company’s growth plans. In 2019, AskNicely raised $10 million in Series A funding and expanded on its core NPS software by launching the world’s first mobile customer experience coaching app, which helps companies consistently deliver on their brand promise by using real-time feedback to coach employees.
“I am delighted that AskNicely has chosen to set up its operations in the Netherlands and house its European activities here,” said Jeroen Nijland, Commissioner at the Netherlands Foreign Investment Agency (NFIA), from the Dutch Ministry of Economic Affairs. “AskNicely selecting the Netherlands is further proof that our country is very attractive for global businesses operating at the forefront of information and technological developments.”
The expansion is led by Vice President and General Manager Europe Kyle Bolster, who previously served as the first AskNicely sales leader and developed the company’s go-to-market strategy. Bolster plans to add up to a dozen Amsterdam employees across sales and customer success teams over the next year, focused on growth and providing exceptional service to existing European clients.
“We’re here to make our users’ lives easy. Thanks to AskNicely, we continuously improve our understanding of our users’ wants and needs,” said Ali Niknam, founder and CEO of European challenger bank bunq . “Welcome to Europe, AskNicely!”
AskNicely was founded in New Zealand in 2014, and the company’s 27-person technology and engineering staff remain based in Auckland. In 2017, AskNicely opened its first U.S. office in Portland, Oregon. Now the company’s official headquarters, its Portland office is home to 50 employees across marketing, sales, customer success, finance and human resources.
“We understand the importance of having localized staff to support our customers,” said Ward. “But we also prioritized choosing a European home that aligns with our company culture, which is very important to us. We chose to base our U.S. operations in Portland because of its commonalities with New Zealand: its culture, its affordable standard of living, and its ethos around customer experience. We feel that Amsterdam shares much of the same DNA and will be the ideal place for AskNicely to flourish in Europe.”
About AskNicely
AskNicely helps people-powered businesses deliver on their brand promise every day. Over a thousand companies around the globe trust AskNicely to understand and improve their customer experience, using the Net Promoter Score (NPS) framework for measurement and the principle of positive recognition for motivating front-line employee performance. Learn more at asknicely.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200122005751/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom